Advertisement
The Company's presentation will take place at 3:00 p.m. (Eastern) onWednesday, November 28, 2007. There will be a live webcast of thepresentation, which will be accessible through a link posted on the Alloswebsite home page and investor relations section. The webcast will beavailable for replay on Allos' website through December 14, 2007.
Advertisement
About Allos Therapeutics, Inc.
Allos Therapeutics is a biopharmaceutical company focused on thedevelopment and commercialization of small molecule therapeutics for thetreatment of cancer. The Company's lead product candidate, PDX(pralatrexate), is a novel antifolate currently under evaluation in a pivotalPhase 2 (PROPEL) trial in patients with relapsed or refractory peripheralT-cell lymphoma. The PROPEL trial is being conducted under an agreementreached with the U.S. Food and Drug Administration under its special protocolassessment, or SPA process. The Company is also investigating PDX in patientswith non-small cell lung cancer and a range of lymphoma sub-types. TheCompany's other product candidate is RH1, a targeted chemotherapeutic agentcurrently being evaluated in a Phase 1 trial in patients with advanced solidtumors and non-Hodgkins Lymphoma (NHL). For additional information, pleasevisit the Company's website at http://www.allos.com.
Safe Harbor Statement
The anticipated presentation will contain forward-looking statements thatinvolve significant risks and uncertainties. Additional informationconcerning these forward-looking statements and other factors that may causeactual results to differ materially from those anticipated in theforward-looking statements is contained in the "Risk Factors" section of theCompany's Annual Report on Form 10-K for the year ended December 31, 2006 andin the Company's other periodic reports and filings with the Securities andExchange Commission. The Company cautions investors not to place unduereliance on the forward-looking statements contained in the presentation. Allforward-looking statements are based on information currently available to theCompany on the date thereof, and the Company undertakes no obligation torevise or update these forward-looking statements to reflect events orcircumstances after the date of this presentation, except as required by law.
SOURCE Allos Therapeutics, Inc.
